A highly qualified “thank you” to Drs. Welch and Albertsen — maybe?

The prostate cancer patient community should be aware of an “op-ed” in today’s New York Times by Drs. Gilbert Welch and Peter Albertsen arguing that Medicare should continue to let individual physicians make their own decisions about the use of the PSA test for risk of prostate cancer. … READ MORE …

The prognostic value of PSA kinetics in untreated men with prostate cancer

The question of whether PSA kinetics (e.g., PSA doubling time and PSA velocity) can be used to accurately project risk for prostate cancer progression and mortality is still not definitively known (although it is much debated). … READ MORE …

Getting a repeat PSA test prior to biopsy … value now confirmed

For quite a while now The “New” Prostate Cancer InfoLink and many others have been advising men who get a single, somewhat elevated PSA test result to get that test repeated before they make any decisions about what else they may need to do. … READ MORE …

Prostate Cancer International submits comment on CMS proposal to discourage PSA testing

Prostate Cancer International and The “New” Prostate Cancer InfoLink have never been supportive of the use of annual, mass, population-wide PSA screening of men over the ages of about 40 or 50 years as a way to identify risk for prostate cancer. … READ MORE …

CMS issues inappropriate proposal to “discourage the use of PSA-based screening”

Apparently our friends at the Centers for Medicare and Medicaid Services (CMS) have misunderstood the details of the D recommendation about PSA screening for prostate cancer issued by the U.S. Preventive Services Task Force (USPSTF) in 2012, … READ MORE …

New multi-biomarker test accurate in detection of clinically significant prostate cancer

A newly published study in The Lancet Oncology has provided some very interesting data on the accuracy of a new, multi-biomarker test in screening 50- to 69-year-old men for risk of prostate cancer. … READ MORE …

Low PSA + Gleason 8 to 10 disease predictive of higher risk, worse survival

It has been hypothesized for some time that men diagnosed with a low PSA level (i.e., < 4.0 ng/ml) but a high Gleason score (of 8, 9, or 10) are at elevated risk for more advanced disease and a shorter survival time than some others. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,368 other followers